Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H33ClN2O5S.ClH.H2O |
Molecular Weight | 479.459 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.[H][C@@](NC(=O)[C@@H]1C[C@@H](CCC)CN1C)([C@H](C)Cl)[C@@]2([H])O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O
InChI
InChIKey=KWMXKEGEOADCEQ-WNNJHRBUSA-N
InChI=1S/C18H33ClN2O5S.ClH.H2O/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H;1H2/t9-,10+,11-,12+,13-,14+,15+,16+,18+;;/m0../s1
Molecular Formula | C18H33ClN2O5S |
Molecular Weight | 424.983 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdfCurator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050162s092s093lbl.pdfhttp://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050441s072,050639s033lbl.pdf
Curator's Comment: description was created based on several sources, including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050537s035,050600s013,050615s012lbl.pdf | http://www.rxlist.com/clindamycin-phosphate-topical-solution-drug.htm
Clindamycin phosphate is the prodrug of clindamycin with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis. It is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes; Skin and skin structure infections; Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes; Intra-abdominal infections; Septicemia; Bone and joint infections. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Abdominal pain, gastrointestinal disturbances, gram-negative folliculitis, eye pain and contact dermatitis have also been reported in association with the use of topical formulations of clindamycin. Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC105985/pdf/ac003014.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/9797245
Curator's Comment: Clindamycin phosphate is the prodrug of clindamycin
with no antimicrobial activity in vitro but can be rapidly converted in vivo to the parent drug, clindamycin, by phosphatase ester hydrolysis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12860123 |
|||
Target ID: CHEMBL2363135 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN HYDROCHLORIDE Approved UseClindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus. Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1970 |
|||
Curative | CLEOCIN T Approved UseClindamycin Phosphate is indicated in the treatment of acne vulgaris. Launch Date1980 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseLower respiratory tract infections including pneumonia, empyema, and lung abscess
caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis),
and Staphylococcus aureus. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSkin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus
aureus, and anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseGynecological infections including endometritis, nongonococcal tubo-ovarian abscess,
pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseIntra-abdominal infections including peritonitis and intra-abdominal abscess caused by
susceptible anaerobic organisms. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseSepticemia caused by Staphylococcus aureus, streptococci (except Enterococcus
faecalis), and susceptible anaerobes. Launch Date1972 |
|||
Curative | CLEOCIN PHOSPHATE Approved UseBone and joint infections including acute hematogenous osteomyelitis caused by
Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic
bone and joint infections due to susceptible organisms. Launch Date1972 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
0.92 ng/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
13.54 ng × h/mL |
0.03 g 1 times / day steady-state, topical dose: 0.03 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10475141/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLINDAMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Disc. AE: Vaginal pain or burning... AEs leading to discontinuation/dose reduction: Vaginal pain or burning (1.2%) Sources: Page: p.571 |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Disc. AE: Diarrhea, Clostridium difficile, Anaphylactic shock... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Anaphylactic shock Hypersensitivity reaction (severe) |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Disc. AE: Diarrhea, Clostridium difficile, Reaction skin... AEs leading to discontinuation/dose reduction: Diarrhea, Clostridium difficile Sources: Page: p.1Reaction skin (severe) Toxic epidermal necrolysis (grade 3-5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Vaginal pain or burning | 1.2% Disc. AE |
5 g 7 times / day multiple, vaginal Recommended Dose: 5 g, 7 times / day Route: vaginal Route: multiple Dose: 5 g, 7 times / day Sources: Page: p.571 |
unhealthy, 16 - 51 n = 79 Health Status: unhealthy Condition: Bacterial Vaginosis Age Group: 16 - 51 Sex: F Population Size: 79 Sources: Page: p.571 |
Anaphylactic shock | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
1200 mg 4 times / day multiple, intravenous Recommended Dose: 1200 mg, 4 times / day Route: intravenous Route: multiple Dose: 1200 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intramuscular Recommended Dose: 300 mg, 4 times / day Route: intramuscular Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Anaphylactic shock | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Hypersensitivity reaction | severe Disc. AE |
300 mg 4 times / day multiple, intravenous Recommended Dose: 300 mg, 4 times / day Route: intravenous Route: multiple Dose: 300 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: |
Diarrhea, Clostridium difficile | Disc. AE | 450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Toxic epidermal necrolysis | grade 3-5 Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Reaction skin | severe Disc. AE |
450 mg 4 times / day multiple, oral Recommended Dose: 450 mg, 4 times / day Route: oral Route: multiple Dose: 450 mg, 4 times / day Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Infections due to susceptible strains of streptococci, pneumococci, and staphylococci Sources: Page: p.1 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 1.0 |
moderate [Inhibition 100 uM] | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 7;9 |
no |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
minor | likely (co-administration study) Comment: inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin Page: 5.0 |
|||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/12814964/ Page: 5.0 |
not determined |
PubMed
Title | Date | PubMed |
---|---|---|
Lemierre's syndrome with spondylitis and pulmonary and gluteal abscesses associated with Mycoplasma pneumoniae pneumonia. | 2001 Apr |
|
Chronic granulomatous disease: a case report. | 2001 Apr |
|
Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. | 2001 Apr |
|
Severe babesiosis in Long Island: review of 34 cases and their complications. | 2001 Apr 15 |
|
Clindamycin suspension and endocarditis prophylaxis. | 2001 Apr 28 |
|
Laparoscopic management of adnexal masses. | 2001 Apr-Jun |
|
A combination benzoyl peroxide and clindamycin topical gel compared with benzoyl peroxide, clindamycin phosphate, and vehicle in the treatment of acne vulgaris. | 2001 Feb |
|
Are 2 combined antimicrobial mechanisms better than 1 for the treatment of acne vulgaris? Clinical and antimicrobial results of a topical combination product containing 1% clindamycin and 5% benzoyl peroxide. Introduction. | 2001 Feb |
|
Potential role for a new combination topical therapy in treating mild to moderate acne vulgaris. | 2001 Feb |
|
The development of antibiotic resistance in Propionibacterium acnes. | 2001 Feb |
|
Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. | 2001 Feb |
|
Two cases of diskitis attributable to anaerobic bacteria in children. | 2001 Feb |
|
Folliculitis decalvans. | 2001 Jan |
|
Two cases of severe bronchopneumonia due to influenza A (H3N2) virus: detection of influenza virus gene using reverse transcription polymerase chain reaction. | 2001 Jan |
|
The association of elevated percent bands on admission with failure and complications of interval appendectomy. | 2001 Jan |
|
Treatment of dogs infected with Hepatozoon americanum: 53 cases (1989-1998). | 2001 Jan 1 |
|
Xerostomia, xerophthalmia, and plasmacytic infiltrates of the salivary glands (Sjögren's-like syndrome) in a cat. | 2001 Jan 1 |
|
The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. | 2001 Jan-Feb |
|
Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. | 2001 Jul |
|
A rare case of primary group A streptococcal peritonitis. | 2001 Jul |
|
Susceptibility of the Bacteroides fragilis group to newer quinolones and other standard anti-anaerobic agents. | 2001 Jul |
|
Elution characteristics of vancomycin, teicoplanin, gentamicin and clindamycin from calcium sulphate beads. | 2001 Jul |
|
Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae. | 2001 Jun |
|
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea. | 2001 Jun |
|
[Chronic osteomyelitis of the ilium after autologous bone harvesting in Albers-Schonberg osteopetrosis. A case report]. | 2001 Jun |
|
Transfusion-transmitted babesiosis in Ontario: first reported case in Canada. | 2001 Jun 12 |
|
A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. | 2001 Jun 25 |
|
[Antibiotic prophylaxis in oncologic pharyngolaryngeal surgery: ceftriaxone versus clindamycin and gentamycin]. | 2001 Mar |
|
[Ocular parasitoses and mycoses: cases diagnosed in the Central University Hospital of Sfax between 1996 and 1999]. | 2001 Mar |
|
Persistence of Plasmodium falciparum in the placenta after apparently effective quinidine/clindamycin therapy. | 2001 Mar |
|
[The therapeutic approach to necrotizing fasciitis]. | 2001 Mar |
|
[Cellulitis and necrotizing fasciitis: microbiology and pathogenesis]. | 2001 Mar |
|
Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. | 2001 Mar |
|
In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. | 2001 Mar |
|
Antibiotic-resistant bacteria in pediatric chronic sinusitis. | 2001 Mar |
|
Detection and characterization of a bacteriocin, garviecin L1-5, produced by Lactococcus garvieae isolated from raw cow's milk. | 2001 Mar |
|
Antibiotic resistance rates and macrolide resistance phenotypes of viridans group streptococci from the oropharynx of healthy Greek children. | 2001 Mar |
|
Tufted hair folliculitis after scalp injury. | 2001 Mar |
|
Sequential parapharyngeal abscesses. | 2001 Mar |
|
Phenotypic and genotypic characterization of macrolide-resistant group A Streptococcus strains in the province of Quebec, Canada. | 2001 Mar |
|
Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. | 2001 Mar 30 |
|
Serotyping and antimicrobial susceptibility of group B Streptococcus over an eight-year period in southern Taiwan. | 2001 May |
|
Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures. | 2001 May |
|
When to suspect and how to monitor babesiosis. | 2001 May 15 |
|
Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. | 2001 May 15 |
|
Sensitive and specific determination of clindamycin in human serum and bone tissue applying liquid chromatography-atmospheric pressure chemical ionization-mass spectrometry. | 2001 May 5 |
|
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. | 2001 May-Jun |
|
Prevalence of serotypes and molecular epidemiology of Streptococcus pneumoniae strains isolated from children in Beijing, China: identification of two novel multiply-resistant clones. | 2001 Spring |
|
In vitro activity of 19 antimicrobial agents against enterococci from healthy subjects and hospitalized patients and use of an ace gene probe from Enterococcus faecalis for species identification. | 2001 Spring |
|
Erythromycin and amoxicillin? | 2001 Winter |
Sample Use Guides
150 to 300 mg every 6 hours (Serious infections), 300 to 450 mg every 6 hours (More severe infections), 8 to 16 mg/kg/day divided into three or four equal doses (Serious infections in pediatric patients), 16 to 20 mg/kg/day divided into three or four equal doses (More severe infections in pediatric patients).
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: The Minimum Inhibitory Concentration was 0.03-0.12 ug/ml (Streptococcus pneumoniae ATCC 49619) when testing aerobic pathogens and 0.06-0.25 ug/ml (Eubacterium lentum ATCC 43055) when testing anaerobs.
MIC=0.03-0.12 ug/ml (Aerobic Pathogens), MIC=0.06-0.25 ug/ml (Anaerobes).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:33:51 GMT 2023
by
admin
on
Fri Dec 15 16:33:51 GMT 2023
|
Record UNII |
ZNC153389R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C82922
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53302336
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
m3624
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
SUB31635
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
58207-19-5
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
ZNC153389R
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
C83630
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY | |||
|
100000124213
Created by
admin on Fri Dec 15 16:33:51 GMT 2023 , Edited by admin on Fri Dec 15 16:33:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |